Anti-RBD-4 antibody (Casirivimab)
| Size | 100µg |
|---|---|
| Brand | |
| Product type | |
| Clonality |
| Product name | Anti-RBD-4 antibody (Casirivimab) |
|---|---|
| Species | Human |
| Expression system | Mammalian |
| Molecular weight | 150kDa |
| Purity | 85% |
| Buffer | PBS, pH7,5 |
| Form | Liquid |
| Delivery condition | Dry ice |
| Storage condition | 4°C for short term; -20°c or -80°C for long term |
| Brand | Proteogenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | REGN10933 |
| Reference | PTXCOV-A552 |
| Related Products | RBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant,RBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant,SARS-CoV-2 RBD of Spike protein, K417N, E484K, N501Y – B.1.351 lineage – SA Beta Variant,SARS-CoV-2 RBD of Spike protein, E484K |
| Note | For research use only. Not suitable for in vitro diagnostic and human use. |
| Isotype | IgG1 |
| Clonality | Monoclonal Antibody |
| Target | RBD domain- SARS-CoV2 Spike protein for first type and variants (PX-COV-P046, PX-COV-P052, PX-COV-P053, PX-COV-P056) |
General information on Anti-RBD-4 antibody
The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the most important target for the design of novel therapies for COVID-19. The development of antibodies that can target this specific area can be done in vivo, which is a time-consuming in vitro process or which can take advantage of the flexibility of visualization technologies such as pH age visualization. Anti-CoV-RBD antibody was developed by pHa to visualize the extensive library of COVID-19 (LiAb-SFCOVID-19 â„¢) antibodies against SARS-CoV-2 RBD. Whereas generation of antibodies based on pH age does not require animal immunization or the use of immunogenic antigens, only small RBD proteins are used to isolate specific RBD ligands from the LiAb-SFCOVID-19 TM library. Furthermore, since the library is composed of immune libraries from COVID-19 patients, it possesses the largest and most important biological antibodies with important neutralizing activities.
Therefore, this specific antibody is a fully human immunoglobulin in IgG format. The ELISA (Enzyme-linked immunosorbent assay) test was used to test and verify its affinity for recombinantly expressed RBD. In addition, the neutralizing activity was tested by the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), which is designed to rapidly assess the neutralization potential of new antibodies without using natural viral particles.
Finally, IgG antibodies are expressed in the XtenCHO â„¢ high throughput mammalian transient system, exhibit very stable stability and consistently produce high yields.
SDS-PAGE for Anti-RBD-4 antibody
Anti-RBD-4 antibody (Casirivimab), on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Related products
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants(9.44 ng/mL for the wild type, 5.23 ng/mL for Alpha, >500 ng/mL for Gamma, 1.94 ng/mL for Delta).
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants(9.44 ng/mL for the wild type, 5.23 ng/mL for Alpha, >500 ng/mL for Gamma, 1.94 ng/mL for Delta).